West Pharmaceutical Services Inc (WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Symbol
WST
Exchange
NYSE
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$25.69B
52 week range
223.83 - 386

Valuation

Share price
$364.98 (close of 2026-10-02)
P/E (TTM)
46.38x
Price to book
8.59x
Price to free cash flow
58.81x
Enterprise value
$25.57B
Book value per share
$42.47

Price performance

PeriodChange
1 day-0.01%
5 days-1.47%
1 month+6.52%
3 months-0.21%
6 months+43.24%
Year to date+32.65%
1 year+33.61%
3 years-1.51%
5 years-13.04%
10 years+389.91%
All time+46692.31%

Members of Congress who disclosed WST trades

Lisa McClain · Robert Bresnahan · Jared Moskowitz

Super investors holding WST

Bill Gates (Gates Foundation Trust) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Hillman Capital (Hillman Capital Management, Inc)

Profitability and growth

Return on equity
15.54%
Return on invested capital
17.12%
Return on assets
11.56%
Return on capital employed
16.18%
Gross margin
35.91%
Net margin
16.06%
EBITDA margin
24.60%
Revenue growth
6.25%
Net income growth
0.20%
Free cash flow growth
69.65%

Cash flow and balance sheet

Free cash flow yield (TTM)
1.70%
Current ratio
2.82x
Net debt to EBITDA
-0.14x

Latest reported year

Period end
2025-12-31
Fiscal year
2025
Revenue
$3.07B
Cost of revenue
$1.97B
Gross profit
$1.10B
EBITDA
$756.30M
Net income
$493.70M
Earnings per share
$6.83
Research and development
$74.30M
Shares outstanding
72.30M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$3.07B$1.10B$493.70M$6.83
2024-12-31$2.89B$998.50M$492.70M$6.75
2023-12-31$2.95B$1.13B$593.40M$7.98
2022-12-31$2.89B$1.14B$585.90M$7.87
2021-12-31$2.83B$1.18B$661.80M$8.89
2020-12-31$2.15B$767.80M$346.20M$4.68
2019-12-31$1.84B$605.70M$241.70M$3.27
2018-12-31$1.72B$545.40M$206.90M$2.80
2017-12-31$1.60B$512.90M$150.70M$2.04
2016-12-31$1.51B$501.40M$143.60M$1.96

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3135.91%16.06%15.54%17.12%
2024-12-3134.51%17.03%18.37%18.50%
2023-12-3138.28%20.12%20.60%23.70%
2022-12-3139.36%20.30%21.82%29.37%
2021-12-3141.52%23.37%28.34%33.99%
2020-12-3135.76%16.13%18.67%21.37%
2019-12-3132.92%13.14%15.36%16.24%
2018-12-3131.76%12.05%14.82%15.85%
2017-12-3132.07%9.42%11.77%11.68%
2016-12-3133.23%9.52%12.85%12.32%

Cash and debt by year

Period endCashDebt
2025-12-31$791.30M$202.80M
2024-12-31$484.60M$202.60M
2023-12-31$853.90M$72.80M
2022-12-31$894.30M$206.70M
2021-12-31$762.60M$208.80M
2020-12-31$615.50M$252.90M
2019-12-31$439.10M$255.00M
2018-12-31$337.40M$196.00M
2017-12-31$235.90M$197.00M
2016-12-31$203.00M$226.20M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$468.90M$23.80M
2024-12-31$276.40M$18.70M
2023-12-31$414.50M$23.30M
2022-12-31$439.40M$23.70M
2021-12-31$330.60M$37.50M
2020-12-31$298.10M$34.00M
2019-12-31$240.80M$24.40M
2018-12-31$183.90M$15.10M
2017-12-31$132.50M$16.10M
2016-12-31$49.20M$19.50M

Dividend history

Most recent payment
2026-07-29
Paid in the last twelve months
$0.88
Payment dateDividend per share
2026-07-29$0.22
2026-04-29$0.22
2026-01-28$0.22
2025-11-12$0.22
2025-07-30$0.21
2025-04-30$0.21
2025-02-07$0.21
2024-11-13$0.21

Investor relations

Next earnings report

Next confirmed report
2026-10-22
Consensus EPS estimate
$2.18

Past earnings dates

ReportedFiscal periodEPS estimate
2026-07-23Jun/2026$2.08
2026-04-23Mar/2026$1.68
2026-02-12Dec/2025$1.83
2025-10-23Sep/2025$1.67
2025-07-24Jun/2025$1.51
2025-04-24Mar/2025$1.22
2025-02-13Dec/2024$1.75
2024-10-24Sep/2024$1.51

Filings and sources

Company website
westpharma.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Solventum Corp (SOLV) · Medline Inc. (MDLN) · Baxter International Inc (BAX) · Alcon Inc (ALC) · Repligen Corp (RGEN) · ResMed Inc (RMD) · Cooper Companies, Inc. (COO) · Becton Dickinson & Co (BDX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades